title: Dietary arginine alters time of symptom onset in Huntington's disease transgenic mice.
abstract: Recent neuroimaging studies reported complex changes in cerebral blood flow (CBF) in early-staged Huntington's disease (HD) patients. Deckel and co-workers [Deckel and Duffy, Brain Res. (in press); Deckel and Cohen, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 24 (2000) 193; Deckel et al., Neurology 51 (1998) 1576; Deckel et al., J. Nucl. Med. 41 (2000) 773] suggested that these findings might be accounted for, in part, by alterations in cerebral nitric oxide (NO) and its byproduct, peroxynitrite. The current experiment tested this hypothesis by altering NO levels via manipulations of dietary L-arginine (ARG), the dietary precursor of NO, in mice transgenic for HD. Seventy-one mice were assigned at 12 weeks of age to one of three isocaloric diets that varied in their content of ARG. These diets included: (a) 0% ARG, (b) 1.2% ARG (i.e. typical mouse chow), or (c) 5% ARG. The 5% ARG diets in HD mice accelerated the time of onset of body weight loss (P<0.05) and motor impairments (P<0.05), and increased resting CBF in HD relative to control (P<0.05). Conversely, the 0% ARG diet demonstrated no loss of body weight and had no changes in CBF relative to controls. However, the 0% ARG HD group continued to show significant deficits on motor testing (P<0. 05). The 1.2% ARG HD group showed reduced body weight loss, better motor functioning, and fewer changes in CBF compared to the 5% ARG HD group. Immunocytochemistry analysis found greater deposition of nitrotyrosine in the cortex, and vasculature, of HD+ mice, 5% and 1. 2%>0% arginine diets. When collapsed across all conditions, CBF inversely correlated (P<0.05) both with the body weight and motor changes suggesting that changes in CBF are associated with behavioral decline in HD mice. Collectively, these findings indicate that dietary consumption of the NO precursor ARG has a measurable, but complex, effect on symptom progression in HD transgenic mice, and implicates NO in the pathophysiology of HD.
authors.affiliation: Department of Psychiatry, MC 2103, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-2103, USA. deckel@psychiatry.uchc.edu
authors.forename: A W
authors.initials: AW
authors.lastname: Deckel
authors.forename: P
authors.initials: P
authors.lastname: Volmer
authors.forename: R
authors.initials: R
authors.lastname: Weiner
authors.forename: K A
authors.initials: KA
authors.lastname: Gary
authors.forename: J
authors.initials: J
authors.lastname: Covault
authors.forename: D
authors.initials: D
authors.lastname: Sasso
authors.forename: N
authors.initials: N
authors.lastname: Schmerler
authors.forename: D
authors.initials: D
authors.lastname: Watts
authors.forename: Z
authors.initials: Z
authors.lastname: Yan
authors.forename: I
authors.initials: I
authors.lastname: Abeles
mesh_terms: D000818:Animals; D001120:Arginine / Q000008:administration & dosage* / Q000494:pharmacology; D001786:Blood Glucose / Q000032:analysis; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004032:Diet; D006816:Huntington Disease / Q000150:complications / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D051379:Mice; D008822:Mice, Transgenic / Q000235:genetics; D009069:Movement Disorders / Q000209:etiology; D013997:Time Factors; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000378:metabolism; D015431:Weight Loss
chemical_list: D001786:Blood Glucose; C002744:3-nitrotyrosine; D014443:Tyrosine; D001120:Arginine